# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, ...
HC Wainwright & Co. analyst Yi Chen reiterates Co-Diagnostics (NASDAQ:CODX) with a Neutral and maintains $2 price target.
HC Wainwright & Co. analyst Yi Chen maintains Co-Diagnostics (NASDAQ:CODX) with a Neutral and lowers the price target fr...
Co-Diagnostics (NASDAQ:CODX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0....
Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, ...